Julia Ritterhoff

Low Energy Shock Wave Therapy Induces Angiogenesis in Acute Hind-Limb Ischemia via VEGF Receptor 2 Phosphorylation

Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure

Nrf2-Keap1 signaling in oxidative and reductive stress

Macrophages in immunoregulation and therapeutics

Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities

Reactive oxygen species (ROS) as pleiotropic physiological signalling agents

Essential Roles of Intracellular Calcium Release Channels in Muscle, Brain, Metabolism, and Aging

HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins

Extracorporeal Shockwave Therapy for Peripheral Arterial Disease: A Review of the Potential Mechanisms of Action

Danger in the Intensive Care Unit

Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy

Adeno-associated virus vector as a platform for gene therapy delivery

PPAR control of metabolism and cardiovascular functions

Intravenous Fluids and Acute Kidney Injury

Functions of S100 Proteins

DAMP-sensing receptors in sterile inflammation and inflammatory diseases

Bioenergetics and translational metabolism: implications for genetics, physiology and precision medicine

The Biological Basis for Cardiac Repair After Myocardial Infarction

Branched-chain amino acids in disease

S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll‐like receptor 4

S100A1: A Multifaceted Therapeutic Target in Cardiovascular Disease

S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction

Glucose promotes cell growth by suppressing branched-chain amino acid degradation

Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model

Metabolic Remodeling Promotes Cardiac Hypertrophy by Directing Glucose to Aspartate Biosynthesis

Heart Failure Gene Therapy